Novartis' Bet Pays Off as Advanced Accelerator Applications Wins FDA Nod for Lutathera Post author:Sam Post published:January 25, 2018 Post category:BioPharma The drug is the first available FDA-approved Peptide Receptor Radionuclide Therapy. Source: BioSpace You Might Also Like 11 Most Innovative Life Science Companies in the World February 20, 2018 Better Late Than Never: Novartis, Momenta Win FDA Approval for Delayed MS Drug February 12, 2018 <b>ADC Bio</b> To Invest $11 Million On Bioconjugation Facility September 26, 2017
